COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,870 Articles (22,568 medRxiv, 8,302 bioRxiv)

Most recent first Previous |  Page 805: Articles 8041-8050  | Next

Conformational Flexibility in Neutralization of SARS-CoV-2 by Naturally Elicited Anti-SARS-CoV-2 Antibodies
Li, R., Mor, M., Ma, B., Clark, A. E., Alter, J., Werbner, M., Lee, J., Leibel, S. L., Carlin, A. F., Dassau, M., Gal-Tanamy, M., Croker, B. A., Xiang, Y., Freund, N. T.
10.1101/2022.04.03.486854 — Posted: 2022-04-03
Dietary αKG inhibits SARS CoV-2 infection and rescues inflamed lungs to restore normal O2 saturation in animals
Agarwal, S., Kaur, S., Asuru, T. R., Joshi, G., Shrimali, N. M., Singh, A., Singh, O. N., Srivastva, P., Shrivastava, T., Vrati, S., Surjit, M., Guchhait, P.
10.1101/2022.04.02.486853 — Posted: 2022-04-03
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: international observational federated study based on electronic health records through the 4CE consortium ARDS after SARS-CoV-2 infection on young adult
Moal, B., Orieux, A., Ferte, T., Neuraz, A., Brat, G. A., Avillach, P., Bonzel, C.-L., Cai, T., Cho, K., Cossin, S., Griffier, R., Hanauer, D. A., Haverkamp, C., Ho, Y.-L., Hong, C., Hutch, M. R., Klann, J. G., Le, T. T., Loh, N. H. W., Luo, Y., Makoudjou, A., Morris, M., Mowery, D. L., Olsen, K. L., Patel, L. P., Samayamuthu, M. J., Sanz Vidorreta, F. J., Schriver, E. R., Schubert, P., Verdy, G., Visweswaran, S., Wang, X., Weber, G. M., Xia, Z., Yuan, W., Zhang, H. G., Zöller, D., Kohane, I. S., The Consortium for Clinical Characterization of COVID-19 by EHR (4CE), , Boyer, A., Jouhet, V.
10.1101/2022.03.31.22273257 — Posted: 2022-04-03
Detection of a BA.1/BA.2 recombinant in travelers arriving in Hong Kong, February 2022
Gu, H., Ng, D., Liu, G., Cheng, S., Krishnan, P., Chang, L., Cheuk, S., Hui, M., Lam, T. T.-Y., Peiris, J. S. M., Poon, L.
10.1101/2022.03.28.22273020 — Posted: 2022-04-02
Spatial prediction of COVID-19 pandemic dynamics in the United States
Ak, C., Chitsazan, A. D., Gonen, M., Etzioni, R., Grossberg, A.
10.1101/2022.03.27.22271628 — Posted: 2022-04-02
COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study
Mori, K., Mori, T., Nagata, T., Ando, H., Hino, A., Tateishi, S., Tsuji, M., Muramatsu, K.
10.1101/2022.03.30.22273203 — Posted: 2022-04-02
Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis.
Donlan, A. N., Mallawaarachchi, I., Sasson, J., Preissner, R., Loomba, J., Petri, W.
10.1101/2022.03.30.22273174 — Posted: 2022-04-02
Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study)
Kinoshita, T., Shinoda, M., Nisizaki, Y., Shiraki, K., Hirai, Y., Kichikawa, Y., Tsushima, K., Sinkai, M., Komura, N., Yoshida, K., Kido, Y., Kakeya, H., Uemura, N., Kadota, J.
10.1101/2022.03.27.22271988 — Posted: 2022-04-02
Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration.
Belda, F., Mora, O., Lopez-Martinez, M., Torres, N., Vivanco, A., Marfil, S., Pradenas, E., Massanella, M., Blanco, J., Christie, R., Crowley, M.
10.1101/2022.03.28.22272552 — Posted: 2022-04-02
Association of Mass Distribution of Rapid Antigen Tests and SARS-CoV-2 Prevalence: Results from NIH-CDC funded Say Yes! Covid Test program in Michigan
Soni, A., Herbert, C., Baek, J., Shi, Q., Marquez, J., Harman, E., Kheterpal, V., Nowak, C., Suvarna, T., Lin, H., Heetderks, W., Zai, A., Cohen-Wolkowiez, M., Corbie-Smith, G., Kibbe, W., Gerber, B. S., Hafer, N., Barton, B., Broach, J., McManus, D.
10.1101/2022.03.26.22272727 — Posted: 2022-04-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).